• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与世界卫生组织(WHO)Ⅱ型排卵障碍性不孕患者成功诱导排卵相关的因素。

Factors related to successful ovulation induction in patients with WHO group II anovulatory infertility.

机构信息

Merck Serono S.A.-Geneva, Switzerland an affiliate of Merck KGaA, Darmstadt, Germany.

出版信息

Reprod Biomed Online. 2010 Feb;20(2):182-90. doi: 10.1016/j.rbmo.2009.11.017. Epub 2009 Dec 3.

DOI:10.1016/j.rbmo.2009.11.017
PMID:20113956
Abstract

To identify baseline characteristics related to successful ovulation induction, data were analysed from oligo- or anovulatory patients undergoing their first cycle of human recombinant FSH (r-hFSH; follitropin alfa) in a chronic low-dose (75 IU starting dose), step-up protocol in two clinical trials (n=446). Patients were grouped according to response: group A, ovulated within 14 days (75 IU follitropin alfa); group B, ovulated after 14 days (>75 IU follitropin alfa); group C, not administered human chorionic gonadotrophin (HCG) because of poor response; group D, cycle cancelled due to over-response (HCG not administered); group E, spontaneous ovulation prior to obtaining criteria for administration of HCG. Mean body mass index (BMI) of group A (25.0 kg/m(2)) was significantly lower than groups B (27.1 kg/m(2), P<0.001) or C (28.2 kg/m(2), P<0.0001), but similar to group D (24.3 kg/m(2)). Mean antral follicle count (AFC) of group A was also significantly lower than group C (18.3 versus 22.7; P=0.018), but not significantly different from groups B (21.5) or D (19.5); group E had the highest mean AFC (35.7). Comparatively low BMI, low AFC and higher (although still within the normal range) FSH concentration at baseline were associated with successful ovulation induction in infertile women undergoing a chronic low-dose, step-up stimulation protocol.

摘要

为了确定与成功诱导排卵相关的基线特征,对接受两种临床试验(n=446)的首次人重组促卵泡激素(r-hFSH;卵泡刺激素阿尔法)慢性低剂量(起始剂量 75IU)逐步递增方案的少或无排卵患者的数据进行了分析。根据反应将患者分组:A 组,14 天内排卵(75IU 卵泡刺激素阿尔法);B 组,14 天后排卵(>75IU 卵泡刺激素阿尔法);C 组,由于反应不佳未给予人绒毛膜促性腺激素(HCG);D 组,由于过度反应取消周期(未给予 HCG);E 组,在获得给予 HCG 标准之前自发排卵。A 组(25.0kg/m2)的平均体重指数(BMI)明显低于 B 组(27.1kg/m2,P<0.001)或 C 组(28.2kg/m2,P<0.0001),但与 D 组(24.3kg/m2)相似。A 组的平均窦卵泡计数(AFC)也明显低于 C 组(18.3 对 22.7;P=0.018),但与 B 组(21.5)或 D 组(19.5)无显著差异;E 组的 AFC 平均值最高(35.7)。在接受慢性低剂量、逐步递增刺激方案的不孕妇女中,基线时相对较低的 BMI、较低的 AFC 和较高(尽管仍在正常范围内)的 FSH 浓度与成功诱导排卵相关。

相似文献

1
Factors related to successful ovulation induction in patients with WHO group II anovulatory infertility.与世界卫生组织(WHO)Ⅱ型排卵障碍性不孕患者成功诱导排卵相关的因素。
Reprod Biomed Online. 2010 Feb;20(2):182-90. doi: 10.1016/j.rbmo.2009.11.017. Epub 2009 Dec 3.
2
Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial.在世界卫生组织II组无排卵女性中起始剂量为50国际单位重组促卵泡激素的促排卵治疗:IO-50研究,一项前瞻性、观察性、多中心、开放性试验
BJOG. 2003 Dec;110(12):1072-7.
3
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low-dose step-up protocol with weekly increments of 25 international units of follicle-stimulating hormone.在采用每周递增25国际单位促卵泡激素的低剂量逐步递增方案后,无排卵或排卵稀少女性的单卵泡排卵情况得到改善。
Fertil Steril. 2006 Jun;85(6):1766-73. doi: 10.1016/j.fertnstert.2005.11.049.
4
The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO Group II anovulation: a prospective randomized multicentre study.对于采用慢性低剂量递增方案治疗世界卫生组织II组无排卵的患者,使用递减剂量方案:一项前瞻性随机多中心研究。
Hum Reprod. 2006 Nov;21(11):2817-22. doi: 10.1093/humrep/del265. Epub 2006 Jul 27.
5
The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with World Health Organization group II anovulatory infertility.体重对335例世界卫生组织II型无排卵性不孕症女性使用促性腺激素诱导排卵反应的影响。
BJOG. 2006 Oct;113(10):1195-202. doi: 10.1111/j.1471-0528.2006.01034.x. Epub 2006 Aug 10.
6
Recombinant human luteinizing hormone to trigger ovulation: randomized, controlled, dose-finding pilot study in ovulation induction.重组人促黄体生成素用于触发排卵:诱导排卵的随机、对照、剂量探索性试验研究
J Reprod Med. 2014 Jul-Aug;59(7-8):355-66.
7
Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.在微刺激周期中,于卵泡中期使用重组促卵泡激素联合重组促黄体生成素或低剂量重组人绒毛膜促性腺激素进行促排卵对卵巢低反应者的临床效果。
Fertil Steril. 2007 Sep;88(3):665-9. doi: 10.1016/j.fertnstert.2006.11.150. Epub 2007 Feb 12.
8
Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens.用于促性腺激素正常且对克罗米芬耐药的无排卵性不孕症的尿促卵泡素:低剂量递增与递减剂量方案的前瞻性随机比较
J Clin Endocrinol Metab. 1997 Nov;82(11):3597-602. doi: 10.1210/jcem.82.11.4369.
9
Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation.单用低剂量人绒毛膜促性腺激素完成控制性卵巢刺激的疗效
Fertil Steril. 2005 Aug;84(2):394-401. doi: 10.1016/j.fertnstert.2005.02.036.
10
Comparison of different gonadotrophin preparations in intrauterine insemination cycles for the treatment of unexplained infertility: a prospective, randomized study.不同促性腺激素制剂用于宫腔内人工授精周期治疗不明原因不孕症的比较:一项前瞻性随机研究。
Hum Reprod. 2007 Jan;22(1):97-100. doi: 10.1093/humrep/del335. Epub 2006 Sep 5.

引用本文的文献

1
Conception and Concern: A Review of Breast Cancer Risk in Assisted Reproductive Technology.概念与关注:辅助生殖技术中乳腺癌风险综述
Int J Biol Sci. 2025 Mar 24;21(6):2647-2671. doi: 10.7150/ijbs.105357. eCollection 2025.
2
Fertility treatment and breast-cancer incidence: meta-analysis.生育治疗与乳腺癌发病风险:荟萃分析。
BJS Open. 2022 Jan 6;6(1). doi: 10.1093/bjsopen/zrab149.
3
Lipid Metabolic Disorders and Ovarian Hyperstimulation Syndrome: A Retrospective Analysis.脂质代谢紊乱与卵巢过度刺激综合征:一项回顾性分析
Front Physiol. 2020 Nov 19;11:491892. doi: 10.3389/fphys.2020.491892. eCollection 2020.
4
Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management.卵巢过度刺激综合征:关于其病理生理学、危险因素、预防、分类及管理的叙述性综述
Iran J Med Sci. 2018 May;43(3):248-260.
5
Changes in receptivity epithelial cell markers of endometrium after ovarian stimulation treatments: its role during implantation window.卵巢刺激治疗后子宫内膜接受性上皮细胞标志物的变化:其在着床窗期间的作用。
Reprod Health. 2015 May 17;12:45. doi: 10.1186/s12978-015-0034-7.
6
Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction.低剂量重组人促卵泡激素方案用于促排卵诱导的IV期开放标签随机研究。
Reprod Biol Endocrinol. 2014 Jun 18;12:52. doi: 10.1186/1477-7827-12-52.